We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
OZEMPIC Novo Nordisk Pharmaceuticals Pty Ltd
Product name
OZEMPIC
Accepted date
Sep-2025
Active ingredients
Semaglutide
Proposed indication
Ozempic (semaglutide) is proposed to improve claudication in adults with type 2 diabetes and poor blood flow in the legs (a condition called peripheral arterial disease). Claudication refers to pain, cramping, or fatigue in muscles—most often in the legs—that occurs during physical activity and subsides with rest.
Application type
C (new indication)
Publication date
Sep-2025